Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 832049, 7 pages
http://dx.doi.org/10.1155/2015/832049
Review Article

Deep Response in Multiple Myeloma: A Critical Review

1Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
2Department of hematology, Hospital 12 de Octubre, Unidad CRIS, CNIO, University of Madrid, Spain

Received 21 September 2015; Accepted 23 November 2015

Academic Editor: Francesco Di Raimondo

Copyright © 2015 Mariateresa Fulciniti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Novel and more effective treatment strategies against multiple myeloma (MM) have significantly prolonged patients’ survival and raised interest in the depth of response and its association with clinical outcome. Minimal residual disease (MRD) has emerged as one of the most relevant prognostic factors in MM and should be included in a new definition of complete response (CR). Although further standardization is still required, MRD monitoring should be applied in prospective clinical trials as a sensitive tool to compare and evaluate the efficacy of different treatment strategies, particularly in the consolidation and maintenance settings, and implement individualized therapy-monitoring approaches. Here, we review current definition of deep response in MM, advantages and limitations of current MRD assessment assays, clinical evidences for MRD monitoring as a prognostic tool for therapeutic decisions in MM, and challenges to develop uniform criteria for MRD monitoring.